AZBio Board of Directors
David B. Patience
Senior Director – Head of Business Development and Corporate Development
David B. Patience is currently Senior Director – Head of Business Development and Corporate Development for Accelerate Diagnostics an in vitro diagnostics company dedicated to providing solutions for the global challenge of antibiotic resistance and hospital acquired infections. Established in 1987, the company began research activity for microbiology solutions in 2004 and relaunched in 2012 as Accelerate Diagnostics, Inc. to develop and commercialize its first diagnostic platform. The company is publicly traded on Nasdaq as AXDX.
Patience is responsible for Accelerate Diagnostics’ strategic product portfolio: strategic evaluation and market analysis for organic and in-organic opportunities and leads executive collaboration with R&D, legal, strategic marketing and commercial on technical and commercial feasibility to deliver financial analysis of partnerships, mergers and acquisitions and organic programs for strategic roadmap consideration
He is responsible for corporate financing strategy and execution within capital markets (follow-on, convertible debt, ATM and PIPE transactions) and heads the company’s corporate budgeting process with key stakeholders to set annual revenue, gross margin, operating expenses, net working capital and cash burn targets for executive team and Board of Directors for ratification and execution within strategic framework
Prior to joining Accelerate Diagnostics, Patience’s career includes positions with Morgan Stanley’s Investment Banking Division; at Continental Advisors, and at Nuveen Investments.
David B. Patience was awarded a Master of Business Administration from the University of Chicago Booth School of Business and a B.S. in Business Administration from the University of Colorado Leeds School of Business. He holds Series 3, 7, 66 and 79 Financial Licenses.